AbelZeta Publishes Abstract for ASCO 2024 Annual Meeting

AbelZeta Pharma, Inc., a global clinical-stage biopharmaceutical company specializing in innovative cell-based therapeutic products, has announced the publication of data from its C-CAR031 study. This data is now accessible in an abstract on the American Society of Clinical Oncology's (ASCO) official website, aligning with the company's upcoming oral presentation at the ASCO Annual Meeting in Chicago, scheduled from May 31 to June 4, 2024. The presentation will focus on the safety and preliminary efficacy results of C-CAR031 in a cohort of 24 patients diagnosed with hepatocellular carcinoma (HCC). Interested parties can access the abstracts on the ASCO meeting website.

The oral presentation, titled "Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)," is assigned Abstract Number 4019. It falls under the Rapid Oral Abstract session for Gastrointestinal Cancer, specifically focusing on Gastroesophageal, Pancreatic, and Hepatobiliary cancers. The session is set for June 3, 2024, from 9:45 AM to 11:15 AM CDT.

C-CAR031 is a pioneering therapeutic approach, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy aimed at treating HCC. This therapy incorporates a novel chimeric antigen receptor (CAR) targeting Glypican 3 (GPC3), developed by AstraZeneca using their transforming growth factor-beta receptor II dominant negative (TGFβRIIDN) armoring platform. AbelZeta manufactures this therapy in China and is co-developing it with AstraZeneca under a collaborative agreement.

AbelZeta Pharma, Inc. is headquartered in Rockville, Maryland, with additional centers of excellence in Shanghai, China. The company focuses on developing proprietary cell-based therapeutic products and is dedicated to creating bespoke treatments that leverage the body's immune system to combat hematological malignancies, solid tumors, inflammatory, and immunological diseases. AbelZeta's research and development are conducted in its GMP facilities, facilitating early-stage clinical studies. The company's pipeline includes CAR-T and tumor-infiltrating lymphocyte (TIL) therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!